Strong revenue growth overshadowed by flat PAT and margin compression

Q1 FY27 QoQ revenue 5.9% (call stated 6%); this is modest given 39.7% YoY backdrop

Accounts beyond top 20 contributed 33.4% vs lower baseline; almost doubled YoY in rupee terms

Stated figures; $10-25M cohort now 9 customers, up from 7

Stated metric; grew 25% in last 2 years; no peer benchmark provided but claim uncontradicted

PAT YoY -0.2% (116.2 Cr Q1 FY27 vs ~116.5 Cr Q1 FY26 implied); margin compression from investments

EBITDA margin fell to 16.9% from ~19-20% historical; PAT flat despite 40% revenue growth reveals magnitude of investment drag vs prior quarter tone

105 active customers (+14 QoQ), 33.4% from beyond top 20 (vs lower prior year baseline); Tectonic expanded to Spain; Agentic AOR in advanced discussions vs proof-of-concept in Q4

Taken one-time hit this quarter but management explicit that benefit flows through H2; part of margin recovery bridge to 19-20%

Management noted client has been sharing revenue upticks for 5 months and numbers 'very encouraging'; de-risks Q3 revenue recognition vs prior quarter ambiguity

Priorities: deepen client relationships, move customer pyramid to $50M accounts, expand base, build end-to-end AI solutions. Risks: regulatory (US policy, drug pricing decisions), but outlook stable. Biotech funding selective but M&A robust ($100B+ spend, on pace for largest since 2019).

No delay; narrowing 6-8 quarter range to 6 quarters from Oct 2025 (Q4 FY27). Investments are in sales team (on-site US/Europe), technology stack, capabilities for strategic deals. Tectonic, $1B portfolio brand management—super strategic deals at largest customers with future upside.

Not breaking out organic/inorganic anymore—BioPharm well integrated. Constant currency growth ~2.6-2.7% range (vs 2.5% USD), accounting for euro/GBP exposure (84-85% USD revenue).

Already ~60% output+outcome-based contracts. Hybrid model: FTE component ramps in month 1, output-based ramps 3-4 quarters to full potential ($1-3M deals). Large omnichannel deal ($10M+ ACV) is pure outcome, deferred 3 quarters, but client revenue upticks very encouraging for Q3 start.

Nuanced approach: not training 5k-10k people on GenAI, solving customer problems (cost of asset development, IP). Bottom layer: data universe (Invisage, physician profiling, BioPharm data assets). Cortex platform separates SME from technical layer so not wedded to one model. On top: agents (Content Super App, Medical Writing). Larger pharma companies will deploy on-prem open-weight models due to IP concerns.

Cannot break out—AI embedded in everything for 10+ years (pre-ChatGPT). NLP, ML, computer vision at back of all assets. GenAI is accelerant. Content volumes up 5-7x, cost per unit down. Cannot isolate AI revenue separately.

Yes, confirmed 19-20% range Q4 FY27. Drivers: growth trajectory, GTM investments, business leadership, revenue uptick from contracted Tectonic business (costs not increasing in line with revenue).

Net retention >100%. Renewal cycles Jan-Dec; renewal in absolute terms ~2-3% ±100%. Rate renegotiations 3-5 year cycles. Never lost major enterprise deal in renewals.

No specific FY27 revenue number; qualitative guidance only. Management confident on pipeline conversion and deal ramp, particularly H2. FY26 baseline growth rate not specified but implied mid-30s% range given FY27 'better than' framing.

Reaffirmed from Oct 2025 earnings call. Current Q1 EBITDA 16.9%; recovery driven by deal ramp-up (Tectonic, omnichannel engagement revenue recognition Q3 onwards), workforce transformation benefits, and productivity initiatives.

Management claims workforce and deal factors will offset Q2 wage hike impact; contingent on execution of large deals and revenue recognition timing

Two marquee deals (₹10M+ omnichannel outcome-based, $1B portfolio brand management) carrying costs in Q1-Q2 but revenue starting Q3. Client acceptance criteria for outcome-based deal may slip; adoption pace described as 'measured' on Tectonic.

Management reaffirmed 6-quarter normalization from Oct 2025 (Q4 FY27 target), but contingent on: (1) deal revenue ramp, (2) workforce transformation benefits materializing, (3) productivity initiatives from GenAI scaling. If any slip, target pushed to FY28.

PAT -0.2% YoY (₹116.2 Cr) while revenue +39.7% YoY reveals operating leverage not flowing through. EBITDA margin down 240 bps from historical 19-20% to 16.9%. Not a one-quarter blip; reflects structural investment phase.

Tectonic is described as 'large engagement' with largest customer. If ramp stalls or customer reduces scope, material revenue impact. Though customer expanded to Spain (positive signal), offtake 'measured'.

Q4 FY26 carried 240 bps mark-to-market hit; now adopted designated hedge accounting. Undesignated hedges material until Dec 2026; sudden rupee weakness could hit Q2/Q3 accounting. However, management claims operational margin hedged going forward.